Welcome to our dedicated page for Bioharvest SEC filings (Ticker: BHST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioHarvest Sciences Inc. (NASDAQ: BHST) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer. BioHarvest files reports with the U.S. Securities and Exchange Commission that document its Botanical Synthesis biotechnology business, financial condition, and capital markets activity.
BioHarvest uses Form 6-K to furnish current reports, including unaudited interim condensed consolidated financial statements, management’s discussion and analysis for specific periods, material change reports, and news releases. These filings cover topics such as revenue trends from the VINIA nutraceutical brand, the growth of the CDMO Services division, and updates on technology initiatives like plant-based exosomes and saffron-derived compounds developed with partners.
The company also references its annual reporting on Form 40-F and a shelf registration statement on Form F-3, which supports public offerings of common stock. Related prospectus supplements and underwriting agreements are incorporated into 6-K submissions, providing detail on how BioHarvest raises capital to fund manufacturing expansion, research and development, marketing, and general corporate purposes.
On Stock Titan, AI-powered tools can help interpret BioHarvest’s filings by summarizing key points from lengthy financial statements and management discussions, highlighting items such as segment performance, non-IFRS measures like Adjusted EBITDA, and material changes reported to regulators. Users can also track ongoing 6-K submissions to follow new grants, strategic CDMO contracts, and other disclosed events that shape the company’s Botanical Synthesis and nutraceutical strategy.
BioHarvest Sciences Inc. (BHST) discloses an extensive set of business and financial risks in this prospectus supplement, emphasizing the company's negative operating cash flow and concerns about its ability to continue as a going concern. The filing lists the need for additional capital, reliance on key inputs and e-commerce channels (VINIA.com, VINIA.co.il and Amazon Marketplace), potential subscription volatility, regulatory and manufacturing compliance risks, clinical trial enrollment risks for nutraceutical/cosmeceutical products, intellectual property and patent expiration risks, possible dilution from future financings, and uncertainty about a liquid trading market for the common shares.